Skip to Content

Sartorius AG Pfd Shs - Non-voting SUVPF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2020, the bioprocess division contributed 76% to total revenue and the lab division the remaining 24%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (40% of 2020 sales), the Americas (35%), and Asia-Pacific (25%). Sartorius employs over 10,000 people and has operations in more than 30 countries.

Contact
Otto-Brenner-Strasse 20
Goettingen, NI, 37079, Germany
T +49 5513080
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type
Employees 9,894